Biodefense Grants and Contracts
FY2005 Awards
In fiscal year (FY) 2005, NIAID awarded a number of grants and contracts to expand scientific research and development for biodefense. These initiatives have been categorized according to the following four areas:
- Research Resources—initiatives to build biodefense research capacity and infrastructure
- Product Development—initiatives to support all phases of development of a candidate product or platform technology, including development of vaccines, therapeutics, and diagnostics
- Clinical Research—initiatives to evaluate biodefense therapies, vaccines, and diagnostics
- Basic Research—programs to investigate pathogen biology, host response, microbial genomic sequencing, and proteomics
Details concerning specific initiatives and related award information may be found below.
Centers for Medical Countermeasures Against Radiation
Objective: To establish centers designed to develop new medical products that will protect against, mitigate the effects of, and treat the short- and long-term consequences of radiation exposure due to terrorist attack.
Contact Info
Helen Quill
E-mail: hquill@niaid.nih.gov
Extramural Research Facilities Improvement Program (NCRR/NIAID)
Objective: For the upgrade of existing BSL-2 to BSL-3 or the upgrade of existing BSL-3 laboratories/animal facilities.
Contact Info
NIAID: Nancy Boyd
E-mail: nboyd@niaid.nih.gov
NCRR: Willie McCullough
E-mail: mccullow@niaid.nih.gov
Regional Biocontainment Laboratories
Objective: To support the design and construction of comprehensive BSL-3/4 laboratories as national resources for research and development for biodefense and emerging diseases.
Contact Info
Design and construction: Nancy Boyd
E-mail: nb142q@nih.gov
Science and research: Alicia Dombroski
E-mail: ad211y@nih.gov
Regional Centers of Excellence for Biodefense and Emerging Infectious Disease Research
Objective: To support the development of large, multidisciplinary regional resources for the scientific community, which will provide the scientific information and translational research capacity to make the next generation of therapeutics, vaccines, and diagnostics against NIAID Category A – C Agents.
Contact Info
Rona Hirschberg
E-mail: rhirschberg@nih.gov
Biodefense Countermeasure Development: Project Bioshield
-
Protecting the Immune System Against Radiation: Bioshield Accelerated Product Development
Objective: To support research projects focused on pre-exposure protection of the immune system against damage by radiological or nuclear terrorist attacks, and/or practical methods to replace hematopoietic stem cells, their progeny, or mature cells of the immune system following exposure to immunosuppressive radiation, using authorities provided by Project Bioshield.
Contact Info
Helen Quill
E-mail: hquill@niaid.nih.gov
-
Therapeutics for CDC Category A Agents: Bioshield Accelerated Product Development
Objective: To support research projects focused on the design and/or preclinical development of therapeutics for CDC Category A agents, using authorities provided by Project Bioshield.
Contact Info
Michael Kurilla
E-mail: mkurilla@niaid.nih.gov
Challenge Grants: Biodefense Product Development
Objective: To facilitate collaborative partnerships between government and the private sector for further development of already identified products against NIAID Category A, B, and C high priority pathogens and all stages of product development against Severe Acute Respiratory Syndrome (SARS), including vaccines, adjuvants, therapeutics, diagnostics, and research resources.
Contact Info
Vaccines: Linda Lambert
E-mail: LL153P@nih.gov
Adjuvants: David Winter
E-mail: dwinter@niaid.nih.gov
Therapeutics: Mark Chalberg
E-mail: MC37E@nih.gov
Immunotherapeutics: Alison Deckhut Augustine
E-mail: augustine@niaid.nih.gov
Diagnostics: Maria Giovanni
E-mail: MG37U@nih.gov
Research Resources: John Rogers
E-mail: MR92I@nih.gov
Clinical Studies: Holli Hamilton
E-mail: HH8F@nih.gov
Cooperative Research for the Development of Vaccines, Adjuvants, Therapeutics, Immunotherapeutics, and Diagnostics for Biodefense and SARS (U01, U19)
Objective: To support discovery/design and development of vaccines, therapeutics, adjuvants, and diagnostics for biodefense. This program will help translate research from the target identification stage through target validation to early product development.
Contact Info
Vaccine Research: Clare Schmitt
E-mail: cs453y@nih.gov
Adjuvants Research: David Winter
E-mail: dwinter@niaid.nih.gov
Therapeutics Research: Catherine Laughlin
E-mail: cl28r@nih.gov
Immunotherapeutics Research: Alison Deckhut Augustine
E-mail: augustine@niaid.nih.gov
Diagnostic Research: Robert Hall
E-mail: rhall@niaid.nih.gov
Vector Control Research: Kathryn Aultman
E-mail: ka6z@nih.gov
Development of Improved DTPA for Radionuclide Chelation
Objective: to facilitate the discovery and demonstration of proof-of-concept of prodrugs or alternative formulations of DTPA that when administered orally will provide plasma levels sufficient to decorporate systemic transuranic compounds and which will be easier to use in the event of a radiation emergency.
Contact Info
Bert W. Maidment
E-mail: maidmentb@niaid.nih.gov
Medical Countermeasures Against Radiological Threats: Product Development Support Services
Objective: To provide the expertise, capabilities, facilities, and the full range of product development support services to obtain FDA approval and/or licensure of medical countermeasures against radiation injury in humans. These product development support services could include the following: preclinical screening and efficacy and pharmacology studies, nonclinical safety evaluations, formulation, stability testing and production of candidate drugs, clinical safety and animal efficacy studies.
Contact Info
Bert W. Maidment
E-mail: maidmentb@niaid.nih.gov
Neutralizing Monoclonal Antibodies for Type A Botulinum Neurotoxins
Objective: To develop and manufacture monoclonal antibodies for botulinum neurotoxins A1 and A2, using authorities provided by Project Bioshield.
Contact Info
Katherine Taylor
E-mail: kataylor@niaid.nih.gov
NIAID Small Business Biodefense Program
Objective: To encourage Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) applications to develop therapeutics, vaccines, adjuvants/immunostimulants, diagnostics, and selected resources for biodefense.
Contact Info
Barbara Mulach
E-mail: bmulach@nih.gov
Recombinant Type E Botulinum Neurotoxins Vaccine
Objective: To manufacture a recombinant type E botulinum neurotoxin vaccine, using authorities provided by Project Bioshield.
Contact Info
Martin Crumrine
E-mail: mhcrumrine@nih.gov
Tularemia Vaccine Development Teams
Objective: To support research to identify and evaluate new tularemia vaccine candidates.
Contact Info
Vicki Pierson
E-mail: vpierson@niaid.nih.gov
Disabling Innate Immune Evasion: New Attenuated Vaccines
Objective: To solicit research projects on new approaches for vaccine development, focusing on the human innate immune system as a target for immune evasion by NIAID Category A, B, and C pathogens.
Contact Info
Francesca Macchiarini
E-mail: fm46w@nih.gov
Biodefense and Emerging Infectious Diseases Research Opportunities
Objective: To encourage the submission of investigator-initiated research grant applications in biodefense and select emerging infectious diseases. The goal is to expedite research leading to the diagnosis, prevention and treatment of diseases caused by potential bioterrorism agents.
Contact Info
Samuel Perdue
E-mail: sp189u@nih.gov
Immune Function and Biodefense in Children, Elderly, and Immunocompromised Populations
Objective: To develop novel methods for protecting or treating immunocompromised individuals at risk from bioterror threats. The research program covers the identification of biological mechanisms responsible for increased susceptibility to infection or decreased effectiveness of vaccines in these populations, as well as testing of treatments designed to increase safety or efficacy.
Contact Info
Conrad Mallia
E-mail: cmallia@niaid.nih.gov
Modeling Immunity for Biodefense
Objective: To develop user-friendly mathematical modeling tools to understand host immune responses to infection by, or vaccination against Category A, B, or C priority pathogens, and to guide laboratory experiments of host immune responses against infectious agents.
Contact Info
Alison Deckhut Augustine
E-mail: augustine@niaid.nih.gov
Training and Career Development for Biodefense and Emerging Diseases
Objective: To ensure that an adequate cadre of well-trained and motivated investigators are available to pursue research and development objectives in biodefense and emerging diseases.
Contact Info
Susan Garges
E-mail: sgarges@niaid.nih.gov
back to top